

ASX Release

ANAGRELIDE PROJECT UPDATE

PERTH, AUSTRALIA – 29 Mar 2021: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, is pleased to announce the appointment of Dr Anil K. Sood to its Scientific Advisory Board. SUDA continues to progress with the development of its oral spray formulation of anagrelide to be used as an adjunct therapy for patients with thrombocytosis (elevated platelets) and metastatic disease.

Dr Anil K. Sood

Dr. Anil K. Sood is Professor and Vice Chair for Translational Research in the Departments of Gynecologic Oncology and Cancer Biology and co-director of the Center for RNA Interference and Non-Coding RNA at The University of Texas MD Anderson Cancer Center. He is also Director of the multi-disciplinary Blanton-Davis Ovarian Cancer Research Program. Dr. Sood co-leads the Ovarian Cancer Moon Shot Program.

Dr. Sood received his medical degree from the University of North Carolina, Chapel Hill, North Carolina. Dr. Sood has received major recognition for his research accomplishments including the Hunter Award, the Margaret Greenfield/Carmel Cohen Excellence in Ovarian Cancer Research Prize, and the GCF/Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher. He is an elected member of the American Society for Clinical Investigation (ASCI), the American Association for the Advancement of Science (AAAS), and the Association of American Physicians (AAP). He was appointed as an American Cancer Society Professor in 2017.

Dr. Sood was the lead investigator in a seminal publication that was published in the New England Journal of Medicine, describing the role that platelets play in ovarian cancer in relation to reducing patient survival.

SUDA's CEO and MD, Dr. Michael Baker commented: "We are thrilled that Dr. Sood is joining our scientific advisory board. He has pioneered the research underpinning the role that platelets play in the progression of cancer. We believe that Dr. Sood will add enormously to the program, given his deep understanding of platelet biology in the clinical setting."

For and on behalf of the Board and for further information please contact:

Dr Michael Baker

Chief Executive Officer & Managing Director

SUDA Pharmaceuticals Ltd

Tel +61 (0) 403 468 187

mbaker@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem tartrate for the treatment of short-term insomnia. ZolpiMist is approved by the TGA and is marketed in the USA. SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of migraine headache, motion sickness, drug resistant epilepsy and certain cancers.

For more information, visit www.sudapharma.com